Navigation Links
NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis

ANN ARBOR, Mich., May 22, 2007 /PRNewswire/ -- NanoBio Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of serious infections, today announced positive safety data from its Phase 1 clinical study of NB-002, the company's drug candidate currently in a Phase 2 clinical trial for the topical treatment of onychomycosis.

The Phase 1 clinical study was completed in January 2007 and involved 20 subjects who received twice-daily treatments of NB-002 (0.25% or 0.5%) for 28 days. Subjects were examined on days 1, 3, 7, 14, 28 and 58 for adverse events, dermal irritation and pharmacokinetic sampling. There were no drug- related adverse events, serious adverse events or discontinuations due to adverse events in any of the subjects treated. In addition, plasma drug levels were below the limit of detection (1 ng/mL) at all time points. Based on the remarkable safety profile demonstrated in this clinical study as well as other previously conducted clinical and toxicology studies, a 42-week double-blinded Phase 2 clinical study of NB-002 was initiated by NanoBio in the first quarter of 2007.

James R. Baker, MD, NanoBio's Chairman of the Board and Chief Science Officer, commented, "A unique aspect of products derived from the company's NanoStat(TM) technology is that the treatments are not systemically absorbed and they are selectively toxic to microbes while non-irritating to the skin and mucous membranes. This Phase 1 safety data further confirms that NB-002 will offer a safe alternative to the currently available systemic products. This is a critical factor for individuals affected by onychomycosis, given approximately 95% of people with this disease remain untreated as a result of the serious toxicities associated with the oral medications on the market."

Phase 2 Clinical Study for NB-002

A randomized, double-blinded, placebo-controlled Phase 2 c
'"/>




Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/24/2014)... , Germany , and ... , Exclusive global license from ... SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for ... be targeted by new test, indicate favorable prognosis for ... QIAGEN sees potential for developing companion diagnostics ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, ... provider of medication and supply management solutions and ... call Thursday, July 31, to discuss the Company,s ... Omnicell Second Quarter 2014 earnings conference call and ... PTWho:  , Randall Lipps, chairman, president and chief ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... 2011 Masimo (NASDAQ: ... of Health & Human Services (HHS) has added Critical ... as a national newborn screening standard.  In addition, the ... detection, published online in the Lancet (appearing ...
... or the "Company") (NASDAQ: UNIS ; ASX: UNS) ... to purchase an additional U.S. $500,000 in shares of the ... 30th. These purchases of Unilife shares will be part of ... $1.0 million in shares by September 30th. This ...
Cached Medicine Technology:U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 2U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 3U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 4U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 5U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 6U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 7U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 8U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 9U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 10Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 2Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 3
(Date:7/25/2014)... The Little Gym of Houston will ... July 27 at Discovery Green in downtown Houston. The ... Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire ... “We’re thrilled to be attending and performing at the ... owns the Sugarland-Missouri City location. “We believe in the ...
(Date:7/25/2014)... Art of Facial Surgery has recently stepped up to ... are looking for minor touch-ups to make them more photogenic. ... Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) and ... showed a surprising increase between 2012 and 2013. The ... increased by 7 percent and eyelid surgery increased by 6 ...
(Date:7/25/2014)... Port Washington, NY (PRWEB) July 25, 2014 ... to protecting the rights of consumers comments on a ... the widow of a smoker $23.6 billion in punitive ... which manufactures Kool brand cigarettes. The case is Cynthia ... in 2008 in the Florida First Circuit Court, Escambia ...
(Date:7/25/2014)... 25, 2014 Hastings and Hastings, ... attorney’s fees with regard to personal injury claims, announces ... wide range of legal services for those that have ... another individual or corporation. Free initial consultation services gives ... of a potential personal injury claim . It ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Babies seem ... suggests. By the time women are 34 weeks ... of their mother,s voice reciting a familiar nursery rhyme, ... predominant source of sensory stimulation in the developing fetus," ... University of Florida,s College of Nursing, said in a ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2
... withdrawal of seven lines of their products Cadbury Schweppes ... more products because of salmonella contamination. ,Cadbury, ... withdraw seven lines of chocolates last month after admitting ... ,Reports of further testing and possible withdrawal of ...
... patisseries, Choco Fudge has been adjudged the best cookie amidst ... panel consisted of eminent writers and fashion designers from Kolkata, ... of place at all ITC hotels across the country as ... contest in Kolkata, ITC Hotels aims to give a boost ...
... to a new study, contrast-enhanced sonography compared with sonography ... the assessment of blunt abdominal trauma.// ,Massimo Valentino, ... of our study was to prospectively compare the diagnostic ... detection of solid organ injuries in blunt abdominal trauma ...
... about subject as sex is, perhaps vying with each other ... well known - responsible //for many diseases, failed pregnancy, miscarriage, ... a host of problems, like ADHD in the child and ... woman’s memory and hormonal cycles. ,Women seem to be ...
... H5N1 strain of bird flu has been detected in remote ... country to be hit by bird flu. ,Although ... cases have gone unnoticed. Currently 14 of Nigeria's 36 states ... "We have identified it in three places in Taraba, one ...
... says ‘significant fluctuations in the first hour blood pressure ... ,According to this study patient mortality increases ... rooted to an impaired autoregulation of blood pressure. ... ischemic stroke symptoms of less than 24 hours. Blood ...
Cached Medicine News:Health News:New Tool Found to be Effective in Assessing Blunt Abdominal Trauma 2Health News:Fluctuating BP and Stroke Lowered Patient Survival Rate 2
Half Trial Frames with precision engineering and lightweight material....
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Child...
... Universal Trial Frame comes at a very attractive price. ,The ... Temple length 4 1/8" to 5 1/2" (98 to ... to 30, PD adjustable 24 to 40mm on each ... on each lens: left - 120 to 0 to 135 ...
Medicine Products: